Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.57 |
| ▸ | ACACA | Q13085 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 5/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649137 | 1.00 | ACACB (0.57) | ACACBACACAMTNR1ATAAR1CNR2 | |
| SCHEMBL4376973 | 0.87 | ACACB (0.63) | ACACBACACAMTNR1AGPR35 | |
| SCHEMBL4376978 | 0.87 | ACACB (0.63) | ACACBACACAMTNR1AGPR35 | |
| SCHEMBL9235486 | 0.87 | ACACB (0.75) | ACACBACACAMTNR1A | |
| SCHEMBL8109293 | 0.87 | ACACB (0.75) | ACACBACACAMTNR1A | |
| SCHEMBL647889 | 0.85 | ACACB (0.57) | ACACBACACAMTNR1ACNR2GPR35 | |
| SCHEMBL647888 | 0.85 | ACACB (0.57) | ACACBACACAMTNR1ACNR2GPR35 | |
| SCHEMBL649357 | 0.85 | ACACB (0.57) | ACACBACACAMTNR1AGPR35 | |
| SCHEMBL649358 | 0.85 | ACACB (0.57) | ACACBACACAMTNR1AGPR35 | |
| SCHEMBL649373 | 0.83 | ACACB (0.53) | ACACBMTNR1ATAAR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537096-B1 | DERIVATIVES OF DIOXANE-2-ALKYL CARBAMATES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | EP | claimed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | claimed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | claimed |
| US-8119687-B2 | Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2012-02-21 | — | — | US | disclosed |
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| US-7777057-B2 | 2-Amino-2-oxoethyl trans-3-[5-(naphth-1-yl)-1,3-dioxan-2-yl]propyl carbamate; reacting the phenylcarbonate with 2-aminodioxane; fatty acid amido hydrolase (FAAH) inhibitors; analgesics; nervous system disorders; gastrointestinal disorders,; to name just a few | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-11-02 | — | — | US | disclosed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885ACACA 1418/4885MTNR1A 466/4885 |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885ACACA 1418/4885MTNR1A 466/4885 |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | CHRM3, CHRM2, CHRM4 | ACACB 681/4885ACACA 1128/4885MTNR1A 540/4885 |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885ACACA 1418/4885MTNR1A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.